Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the effect of food on pharmacokinetics, safety and tolerability of an experimental Hepatitis C Virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Detailed Description
This is an open-label, randomized, 2 cross-over period fasting and non-fasting study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: 1 Non-fasting |
Drug: ABT-450
capsules, QD, 1 dose in each cross-over period
Drug: ritonavir
capsule, QD, 1 dose in each cross-over period
Other Names:
|
Active Comparator: 2 Fasting |
Drug: ABT-450
capsules, QD, 1 dose in each cross-over period
Drug: ritonavir
capsule, QD, 1 dose in each cross-over period
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Pharmacokinetics (blood draws, pre- and post-dose) [17 days]
- Safety and tolerability (ECGs, AEs, vitals, physical exams, routine labs) [30 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
overall healthy subjects;
-
non-childbearing potential females included
Exclusion Criteria:
-
history of significant sensitivity to any drug;
-
positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab;
-
history of gastrointestinal issues or procedures;
-
history of seizures, diabetes or cancer (except basal cell carcinoma);
-
clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder;
-
use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration;
-
donation or loss of 550 mL or more blood volume or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration;
-
abnormal screening laboratory results that are considered clinically significant by the investigator;
-
current enrollment in another clinical study;
-
previous enrollment in this study;
-
recent (6-month) history of drug/alcohol abuse that could preclude adherence to the protocol;
-
pregnant or breastfeeding female;
-
requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Site Reference ID/Investigator# 19421 | Waukegan | Illinois | United States | 60085 |
Sponsors and Collaborators
- Abbott
Investigators
- Study Director: Isabelle A Gaultier, M.S., IBMH, Abbott
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- M10-923